LACTEL 75:25 DL-PLG (B6007-1) is a biomedical-grade amorphous poly(DL-lactide-co-glycolide) raw material in which the lactide:glycolide molar ratio is 75:25. The copolymer is produced by ring-opening polymerization of DL-lactide and glycolide; the methyl side groups of the DL-lactide repeat units suppress chain packing and crystallinity, while the glycolide repeat units provide hydrolytically cleavable ester linkages. Because the material is amorphous, differential scanning calorimetry under ISO 11357-2 shows a glass transition rather than a melting endotherm. The B6007-1 designation identifies a specific end-group, inherent-viscosity, residual-monomer, and purification specification within the LACTEL DL-PLG series. Lot-specific certificates of analysis govern exact molar mass, acid number, residual solvent, and residual tin content. The product is typically supplied as a white to off-white powder or granular solid and should be stored below -15°C in sealed, low-moisture packaging to limit hydrolytic pre-degradation and moisture uptake at relative humidity above 60%.

The material is intended as a raw-material input for drug delivery systems, bioresorbable implants, and tissue engineering scaffolds. It is not a finished device and does not by itself establish biological safety or clinical performance. Finished-device validation remains the responsibility of the device manufacturer under the applicable regulatory framework.

What Separates the B6007-1 Grade from Other LACTEL Lactide/Glycolide Copolymers at the Raw-Material Level?

Compared with 50:50 DL-PLG, the 75:25 composition reduces the mole fraction of the more rapidly hydrolyzed glycolate repeat unit. In neutral phosphate-buffered saline at 37°C, hydrolytic chain scission proceeds by the bulk-erosion mechanism common to PLGA, but the lower glycolide content delays the point at which water uptake and autocatalytic oligomer generation produce measurable mass loss. Published comparative in vitro data for thin PLGA films place the mass-loss half-life roughly in the 12–20-week range for 75:25 copolymers, while 50:50 copolymers typically fall in the 4–8-week range. These values depend on molecular weight, end-group chemistry, specimen thickness, and test medium. Published data for the specific B6007-1 configuration are limited; lot-specific degradation testing under ASTM F1635-16 is required before setting a device specification.

At the raw-material level, the 75:25 copolymer has a higher lactide mole fraction than 50:50 DL-PLG, which typically raises the glass transition into the 45–50°C range, compared with 35–45°C for 50:50 material of comparable molecular weight. The lower glycolide content also reduces equilibrium water uptake in the solid state. This property delays the onset of bulk autocatalysis, but it also requires more assertive drying before melt processing because absorbed moisture is less readily released under ambient conditions.

During melt extrusion on production-scale twin-screw equipment, the practical processing window for 75:25 DL-PLG is bounded by the glass transition near 45°C and the onset of thermal chain scission above approximately 180°C. Co-rotating twin-screw extruders with L/D ratios between 24:1 and 40:1 are preferred over single-screw machines because the segmented screw architecture allows low-shear melting and more precise control of filled length. Typical melt-processing campaigns on a 16-mm or 18-mm twin-screw line use barrel zones from 130°C to 160°C, a die temperature below 170°C, and screw speeds from 100 rpm to 200 rpm, with residence time held under 2 min. The exact settings must be revalidated for each lot, because an inherent-viscosity difference of ±0.05 dL/g can shift melt pressure by 8–15% at a fixed feed rate. At the upper end of the barrel profile, the absence of a crystallization exotherm means that thermal overshoot is not absorbed by a crystalline phase transition. Process alarm bands of ±5°C around the validated die set point are therefore common for amorphous PLGA. Pre-drying should reduce moisture to <0.05% w/w by vacuum drying at 25–30°C for at least 24 h; alternative dry-air systems must remain below the glass transition to avoid particle agglomeration. Moisture above 0.10% w/w can produce hydrolytic molecular-weight loss during extrusion, visible as a melt-viscosity reduction and an increase in extractable oligomers in the cooled strand.

Solution Preparation, Microsphere Formation, and Sterilization Constraints

For drug-loaded microsphere preparation, 75:25 DL-PLG is usually dissolved in dichloromethane at 5–15% w/v. Ethyl acetate may be used to reduce chlorinated-solvent burden, but can require higher processing temperatures because of lower polymer solubility. The organic phase is emulsified into an aqueous poly(vinyl alcohol) continuous phase at 0.5–2% w/v using rotor-stator mixers or static mixers, with impeller speeds from 200 rpm to 1,000 rpm depending on target particle size. Solvent removal by evaporation at 25–40°C under reduced pressure yields particles whose size distribution should be checked by laser diffraction under USP <429> and whose residual solvent level should be verified by gas chromatography under USP <467>. The amorphous structure of the B6007-1 material generally favors homogeneous microsphere matrices, but encapsulation efficiency is governed by drug loading, phase ratio, and solvent removal rate rather than by the copolymer grade alone.

Terminal sterilization of finished PLGA microspheres by gamma radiation at 25 kGy can reduce molecular weight by 10–30%; the exact loss depends on package oxygen content, dose rate, and total absorbed dose. Ethylene oxide exposure requires post-sterilization aeration to reduce sorbed gas residuals. Autoclaving is generally unsuitable because the temperature exceeds the glass transition of the polymer and produces particle fusion or geometric distortion in molded devices.

Unlike semicrystalline poly(L-lactide), 75:25 DL-PLG does not develop spherulitic crystallinity during slow cooling from melt processing. This property eliminates the need for post-molding annealing to stabilize crystalline domains and avoids anisotropic shrinkage associated with crystallization. However, the same amorphous structure means that solvent-cast and melt-processed articles must be handled below the glass transition if they are to retain sharp edges and dimensional accuracy. At room temperature and relative humidity below 40%, the material is glassy and dimensionally stable; at body temperature under hydrated conditions it becomes a flexible rubber, which can be beneficial for implant contouring but can also allow creep under static load. Load-bearing applications should therefore evaluate creep behavior by ASTM D2990-17 or ISO 899-1 under simulated in vivo conditions, not from dry-room tensile data alone.

End-group chemistry is a further control parameter. An acid-terminated 75:25 PLGA carries free carboxylic acid chain ends that are ionized at physiological pH, increasing local hydration and electrostatic interaction with cationic drugs. Ester-capped PLGAs lack these free acid groups and often exhibit slower initial hydration and a longer molecular-weight decay delay. Therefore, two 75:25 PLGA lots with identical inherent viscosity can differ in release behavior if their acid numbers diverge. The B6007-1 certificate of analysis should be reviewed for acid number and residual catalyst data before comparative formulation studies are interpreted.

When a Regulatory Filing Requires Raw-Material Release Data Under ISO and Pharmacopeial Methods

For implant or drug delivery applications, the raw-material documentation package is often requested under a medical-device quality system aligned to ISO 13485. Biological evaluation is device-specific under ISO 10993-1; raw-material data alone do not establish biocompatibility of the finished device. Typical raw-material release tests include inherent viscosity by USP <911> or ISO 1628-1, glass transition by ISO 11357-2, residual monomer by gas chromatography with flame ionization detection, residual solvent by USP <467>, tin residue by inductively coupled plasma mass spectrometry, and carboxylic acid content by titration. The finished-device manufacturer remains responsible for demonstrating that extractables, leachables, degradation by-products, and device performance meet the applicable regulatory jurisdiction.

Batch-to-batch variance in 75:25 DL-PLG can arise from differences in polymer lot molecular weight distribution, residual DL-lactide and glycolide content, and end-group termination. These variables affect melt viscosity, solvent solution viscosity, and hydrolytic degradation kinetics. A robust incoming-material specification should therefore include not only identity by Fourier-transform infrared spectroscopy or nuclear magnetic resonance, but also a quantitative release limit for residual monomers and residual tin. When switching among PLGA sources or between acid-terminated and ester-capped grades, equivalence studies should compare molecular weight decay, mass loss, and pH depression in the same buffer system under ASTM F1635-16 conditions, rather than relying solely on nominal lactide:glycolide ratio.

Incompatibility boundaries apply to formulation and processing. Amine-bearing drugs and strongly basic additives can accelerate ester hydrolysis and premature chain scission. Prolonged contact with chlorinated solvents at elevated temperatures may produce acid-catalyzed backbone cleavage. Processing with polycondensation catalysts or metal salts known to promote transesterification should be avoided unless product-specific stability data exist. Because the amorphous matrix has no crystalline reinforcement above its glass transition, sustained static loads in hydrated environments should be assessed by creep or stress-relaxation methods rather than short-term tensile testing alone.